



## Original Article

# OCDB: a database collecting genes, miRNAs and drugs for obsessive-compulsive disorder

Anna P. Privitera<sup>1,2</sup>, Rosario Distefano<sup>3</sup>, Hugo A. Wefer<sup>4</sup>, Alfredo Ferro<sup>1</sup>,  
Alfredo Pulvirenti<sup>1</sup> and Rosalba Giugno<sup>1,\*</sup>

<sup>1</sup>Department of Clinical and Experimental Medicine, University of Catania, Viale A. Doria 6, Catania, Italy, <sup>2</sup>Istituto di Scienze Neurologiche, CNR, Via Paolo Gaifami, 18, 95125 Catania, Italy, <sup>3</sup>Department of Computer Science, University of Verona, Strada le Grazie 15, Verona, Italy and <sup>4</sup>KarolinskaInstitutet, Department of Microbiology, Tumor and Cell Biology, Science for Life Laboratory, Stockholm, Sweden

\*Corresponding author : Fax: + 39 095 330094, Email: [giugno@dmi.unict.it](mailto:giugno@dmi.unict.it)

Citation details: Privitera,A.P., Distefano,R., Wefer, H.A., *et al.* OCDB: a database collecting genes, miRNAs and drugs for obsessive-compulsive disorder. *Database* (2015) Vol. 2015: article ID bav069; doi:10.1093/database/bav069

Received 28 November 2014; Revised 30 April 2015; Accepted 23 June 2015

## Abstract

Obsessive-compulsive disorder (OCD) is a psychiatric condition characterized by intrusive and unwilling thoughts (obsessions) giving rise to anxiety. The patients feel obliged to perform a behavior (compulsions) induced by the obsessions. The World Health Organization ranks OCD as one of the 10 most disabling medical conditions. In the class of Anxiety Disorders, OCD is a pathology that shows an hereditary component. Consequently, an on-line resource collecting and integrating scientific discoveries and genetic evidence about OCD would be helpful to improve the current knowledge on this disorder. We have developed a manually curated database, OCD Database (OCDB), collecting the relations between candidate genes in OCD, microRNAs (miRNAs) involved in the pathophysiology of OCD and drugs used in its treatments. We have screened articles from PubMed and MEDLINE. For each gene, the bibliographic references with a brief description of the gene and the experimental conditions are shown. The database also lists the polymorphisms within genes and its chromosomal regions. OCDB data is enriched with both validated and predicted miRNA-target and drug-target information. The transcription factors regulations, which are also included, are taken from David and TransmiR. Moreover, a scoring function ranks the relevance of data in the OCDB context. The database is also integrated with the main online resources (PubMed, Entrez-gene, HGNC, dbSNP, DrugBank, miRBase, PubChem, Kegg, Disease-ontology and ChEBI). The web interface has been developed using phpMyAdmin and Bootstrap software. This allows (i) to browse data by category and (ii) to navigate in the database by searching genes, miRNAs, drugs, SNPs, regions, drug targets and articles. The data can be exported in textual format as well as the whole database in.sql or tabular format. OCDB is an essential resource to support genome-wide analysis, genetic and pharmacological studies. It also facilitates the evaluation of genetic data in OCD and the detection of alternative treatments.

Database URL: <http://alpha.dmi.unict.it/ocdb/>

## Introduction

Obsessive-compulsive disorder (OCD) is a neurological disease characterized and recognized by intrusive, persistent and unwanted thoughts (obsessions) and repetitive behavior (compulsions). It is a highly debilitating disease because the patients cannot live a normal existence, in fact they have to repeat the same actions or think the same thoughts to obtain a temporary relief (1, 2). The recurrent phenotypes are symmetry/ordering, hoarding, contamination/cleaning, and obsessions/checking (1). Another phenotype is the 'pure obsessional' with sexual, somatic, religious obsessions and mental rituals (2). In some instances, this behavior can include trying to avoid to walk on lines of sidewalks and floors; washing hands or face time after time; sorting objects by size; performing precise thoughts or prayers before entering in a place. OCD affects both children and adults (3, 4). In many cases, the first symptoms appear in childhood and early adolescence. Most of the patients are under the age of 20 (5), and in particular, 21% of the cases are children around the age of 10 years (6). Historically, the guidelines of International Classification of Diseases, 10th revision (ICD-10) and Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM IV TR) classified OCD into the anxiety disorders class (7, 8). The anxiety disorders were a broad and heterogeneous group of disorders including acute stress disorder, agoraphobia and many others (8). Recently, the American Psychiatric Association has published an upgrade in which OCD appears in a separate category called Obsessive-compulsive and related disorders (OCRDs) (9, 10). Thus, there is a growing attention for this disorder, with changes in the diagnostic criteria together with significant clinical implications (11). The World Health Organization, accordingly, ranks OCD as one of the 10 most disabling medical conditions worldwide (12).

OCD was described, for the first time, around a century ago by psychologist Pierre Janet (13). Nowadays, we know that OCD has a genetic component for its origin. The first fundamental OCD genome-wide linkage scan study was conducted by Hanna *et al.* (14) in which they identified regions in chromosomes 2, 9 and 16. Several other similar studies analysed the genetic linkage between 9p24 and OCD, and moreover, a few candidate genes have been identified (15, 16).

Few studies have highlighted the heritability of such a disease. In particular, the early onset of OCD (17) and the ordering/symmetry symptoms of OCD (18) are frequently

heritable. A high risk of developing OCD or some symptoms in first-degree relatives has also been reported (19–21).

We know that in the 9p24 chromosomal region there is a candidate gene associated with OCD, *SLC1A1/EAAC1* (22, 23), which encodes for the neuronal/epithelial high affinity glutamate transporter (23). *SLC1A1* is expressed in some functional areas of the brain (24) and is implicated in OCD in the cortico-striatal-thalamic-cortical circuits (CSTC) (25). Much evidence shows an altered glutamate neurotransmission within CTSC circuits in the pathophysiology of OCD (25). The neuronal glutamate transporter gene (*SLC1A1*) is mainly expressed within CSTC circuits (24). To date, researchers have identified many candidate genes as well as some regions of the genome that might include disease genes (26). Such genes include *SLC6A4* (27, 28), *HTR2A* (29, 30), *HTR2C* (29), *NTRK3* (31) and *SLITRK1* (32).

The nervous system requires an accurate regulation at all control levels. The post-transcriptional regulation of genes has a fundamental role in the pathophysiology of neurologic diseases (33); and for this reason, a great deal of research has been devoted to microRNAs (miRNAs) (34), which constitute a small class of non-coding RNAs. These molecules are ~22 nucleotides (nt) long and are involved in several processes such as gene expression regulation, translational repression, mRNAs degradation and RNA silencing (35, 36). In addition, they also regulate >30% of all protein-coding genes (36). Muiños-Gimeno *et al.* (37) found a role of the neurotrophin-3 receptor gene (*NTRK3*) in the pathophysiology of anxiety disorders. In fact, such a gene has a high variation in the miRNA recognition element (MRE) of miR-485-3p, which is one of the most important miRNA associated to OCD (37). Finally, guidelines to treat OCD include both a psychotherapy called cognitive behavior therapy (CBT) and a pharmacological therapy. CBT is often not enough in 'pure obsessional' because patients have to control many rituals (38). The World Federation of Societies of Biological Psychiatry published the guidelines for the pharmacological treatment of OCD (39). Positive evidence is associated with the usage selective serotonin reuptake inhibitors (SSRIs) such as fluvoxamine, fluoxetine, escitalopram, paroxetine and sertraline, and for tricyclic antidepressant (TCA) such as clomipramine (39).

Despite the efficacy of some approved drugs (such as SSRIs and clomipramine), ~40–60% of patients do not show any significant improvements (40, 41).

Consequently, alternative treatments and new drugs in combination with SSRIs or TCA, might become necessary.

A study based on agomelatine augmentation to escitalopram therapy shows promising results (42). In fact, agomelatine is a 5-HT<sub>2c</sub> receptor antagonist (43) that determines a therapeutic response with total remission of the symptoms and with a Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) (44) score of 5 (initial Y-BOCS score was of 33) (42).

In general, Y-BOCS evaluates the severity of OCD symptoms using a score ranging from 0 and 40. In fact, OCD scores can be 0–7, sub-clinical; 8–15, mild; 16–23, moderate; 24–31, severe; 32–40, extreme (44).

In this work, we propose the first manually curated database, named OCD Database (OCDB), which collects genomic evidence related to OCD from literature. OCDB lists information about genes and chromosomal regions involved in the disease, which include transcription factors, regulations, polymorphisms, predicted and validated miRNAs, drugs targeting such genes, pathways in which genes enter, drugs currently used to treat OCD as well as the related pathologies. Moreover, we have defined a scoring method to assess the relevance to OCD of each item in OCDB. OCDB is equipped with a web interface in which users can search and browse genes, articles, miRNAs, Single-nucleotide polymorphisms (SNPs), drugs, drug targets and chromosomal regions related to OCD. OCDB returns the searched entities with all the information connected to them. Users can save the results in.html and.txt formats. The entire database is also provided in.sql and table formats. OCDB is available online at: <http://alpha.dmi.unict.it/ocdb/>.

## Materials and methods

OCDB is a relational database implemented in MySQL with a web interface that was developed using phpMyAdmin and Bootstrap software. The database is hosted at the University of Catania and is accessible at <http://alpha.dmi.unict.it/ocdb/>

Figure 1 reports the architecture of OCDB. It describes the data extracted from literature and other external resources, how they are linked and the users' assess modes.

### The manually curated data in OCDB

The data stored in OCDB database has been collected from PubMed (45) and Medical Literature Analysis and Retrieval System Online (MEDLINE), updated until March 2015. By querying the earlier databases, we have done a comprehensive search concerning 'OCD and genes, miRNAs, SNPs, drugs, drug therapy and treatments',

'OCD and genes' and 'OCD and genetic association studies'. This yield an outcome of 11 129 articles. Next, we have excluded the articles focusing on the psychological and epidemiological aspects, studies not in human and articles without an English abstract or completely lacking an available abstract. Finally, we obtained 1076 suitable articles for further processing.

A custom Python script, utilizing the Entrez API, helped us to retrieve data from National Center for Biotechnology Information (NCBI) resources (46). Through this, we obtained information about the articles (such as pmid, title, authors, journal, publication year) as well as gene symbols, SNPs and drug names, which were retrieved from Drugbank. In addition, OCDB includes manually curated data extracted from the articles. These include miRNAs names, experimental details (number of the samples, software and technologies used), notes about the scientific results, genomic regions, the role of the genes in the pathologies in comorbidity with OCD, the pharmacodynamics and pharmacological actions (if known) and the effects of the drugs and endogenous molecules on OCD.

The data available in the current version of the database cover 536 publications reporting on 180 polymorphisms in 153 genes and 16 miRNAs, 148 regions, 25 related pathologies as well as 48 drugs.

### OCDB external resources.

To enrich its content, OCDB provides links to several external resources. These include (i) Entrez-gene (v. 2015-04-05)(GRCh38) (46) and HUGO Gene Nomenclature Committee (HGNC) (v.2.0.0 2015-01-19)(GRCh38) (47) to have official gene names and gene\_ids; (ii) Single Nucleotide Polymorphism database (dbSNP) Build 143 (48) to retrieve the rs# numbers of SNPs; (iii) DrugBank (v.4.2) (49) to have information about drugs, such as pharmaceutical categories and therapy indications; (iv) miRBase(v.21) (50) and Pubchem (v. 2015-04-9) (51) to have more research material linked with miRNAs and endogenous molecules, respectively. In addition, transcription factors for genes and miRNAs are obtained from DAVID (v. 6.7) (52, 53) and TransmiR (v.1.2) (54). Genes have been associated to their respective pathways by using Kegg-Pathway (v.2015-04-06) (55, 56). Diseases and drugs have been linked to the disease-ontology (v. 2015-04-18) (57) and ChEBI ontology (v. 2015-04-01) (58), respectively.

### Data prediction.

To help inferring new venues in the treatments and in the underlying genetics, miRNA-gene and drug-targeting predictions have been integrated within OCDB.





- $w_3$ : the number of articles in the database reporting the association among  $A$  and some other pathology, mentioned in the articles, related to OCD.

The score of  $A$  is the linear combination of  $w_1$ ,  $w_2$  and  $w_3$  normalized by z-score. The ratio behind this ranking is that OCDB does not highlight the biological importance of the item itself or the research involving it; but it weights how in our manually curated resource the item is specifically associated to OCD ( $w_1$ ) and to close other related pathologies ( $w_3$ ), and as much information about this item and its ‘neighbors’ (i.e. its relations) can be extracted from OCDB ( $w_2$ ). Consequently, the articles are not classified but instead the items they contain. Finally, the scores are also presented as classes according to the quartile they belong; the quartiles are represented by colors and numbers (red-1, yellow-2, green-3, light blue-4).

### Data interface

The main OCDB interface modules are Search, Advanced Search, Browse and Download/update. These allow (i) to browse the data; (ii) to navigate in the database by searching genes, miRNAs, drugs, articles, SNPs, regions and drug target; and (iii) to download and upload the data.

For each search type, OCDB guides the writing to avoid misspelled inputs. There are two levels of input control checking, a client side and a server side. The input nomenclature is based on the official scientific standard commonly used by online databases. The statistics on the OCDB data are reported together with a brief documentation on the usage of the database content.

### Search and Advanced Search.

The Search section allows users to query the system by genes, miRNAs and drugs. In the Advanced Search, users can query OCDB by article, SNPs, regions and drug target. The drug target section points to genes that are targets of drugs used in the treatments.

Genes are specified by using the nomenclature of HGNC (49) and Entrez-gene by NCBI (46). The nomenclature of miRNAs refers to the ones used in miRBase (50). Drugs are inserted by their names as reported in DrugBank (49). Studies can be retrieved through a full text search by entering the title, the author names or the year of publication. SNPs should be inserted by rs# number corresponding to the nomenclature in dbSNP (48). If the user searches by region, the nomenclature references to cytogenetic standards.

Results are organized in the following cards (see Figure 2). We refer searched genes, miRNAs, drugs, articles, SNPs or genomic regions to as items.

- **Info:** Info gives nomenclature information, links to the web resources and allows downloading a full card of the searched item. If the item is an article, it shows details of the publication (i.e. the title, the author names, the journal, the publication year, note describing the results, if available details on the used techniques, sample and software) together with a link to PubMed (45). When the searched item is a gene, OCDB reports entrez\_id, gene names, aliases, encodes and links to HGNC and NCBI. If the item is a miRNA, the system shows miRBase access number together with a link to the resource. If the item is a drug, OCDB reports the drug names, the drug pharmacodynamics and links to DrugBank and ChEBI. If the item is a SNP, it shows names and NCBI link. Finally, if it is a region, its name is given.
- **Articles:** Articles show references to articles mentioning the item (the title, the author names, the journal, the publication year, note describing the results) and the PMID linking to PubMed (45).
- **Genes:** Genes show the genes, which are targets of the searched miRNA or drug, containing the SNPs or the genes in the searched chromosomal region. It reports the links to HGNC and NCBI, alias, encodes and the role of genes (if the genes are retrieved from articles or if the genes are validated and/or predicted miRNA’s target).
- **Drugs:** If the item is a gene, shows the drugs that have the gene as a target, linked to DrugBank 4.2 (49) together with its type and a description, if available. The data are extracted from DrugBank (49) (targets, transporters and enzymes) or computed by the DT-Hybrid algorithm (62). For all other items, this section reports details on drugs (if any) that in OCDB articles have been associated with the searched item. Details are the gene names linked to Entrez by NCBI (46), endogenous molecules involved and the actions that the drugs has on the targets. There may also be information about the therapeutically indications, pharmacodynamics, pharmacological action and eventually the effects of drug on OCD extracted from the indexed articles.
- **Endogenous molecules:** if the item is a drug, it shows the endogenous molecules and genes on which the drug may have effect and their description. The effect is specified in ‘action’. The name of molecules is linked to PubChem (51).
- **miRNAs:** miRNAs show the miRNA-name linked to miRBase (50). If the item is a gene, it reported the prediction of miRNAs targeting such a gene made by TargetScan (59), miRanda (61) and mirTarBase (60).
- **SNPs:** SNPs show the SNPs present in the item. The SNP name is linked to dbSNP (48). If the item is not a gene, OCDB shows also the gene name linked to Entrez-gene card (46) or the miRNA access number containing the SNP.

**A** Information about the gene

Info Articles Drugs miRNAs SNPs Regions Pathologies Pathways Transcription factors

Gene: ADAR2A  
Alias: RDC2  
Enodes: adenosine-Adz receptor  
Resources: NCBI HGNC  
Download

**B** Information about the gene

Info Articles Drugs miRNAs SNPs Regions Pathologies Pathways Transcription factors

Articles

Show 10 | 1 entries

Study	PubMed ID	Author	Year
Association between ADAR2A and DRD2 polymorphisms and caffeine-induced anxiety	1935461	Author: Chida E, Hoffert C, Deckert J, Xu K, Bacher J, de Wit H Journal: Neuropsychopharmacology. 2008 Nov;33(12):2791-803. doi: 10.1098/npp.2008.17. Epub 2008 Feb 27	2008
Caffeine, mental health, and psychiatric disorders	20184071	Author: Lara DI Journal: J Alzheimers Dis. 2010;20 Suppl 1:S239-48. doi: 10.3233/JAD-2010-1378.	2010
Human miRNAs miR-22, miR-138-2, miR-148a, and miR-489 are associated with panic disorder and regulate several anxiety candidate genes and related pathways	21188126	Author: Muñoz-Grimo M, Espinosa-Parrilla Y, Gardi M, Kögelerauer B, Sola T, Marton E, Patai K, Kananen L, Navas R, Martín-Santosa R, Ortaçso M, Metzpalu A, Hovatta L, Estévil X Journal: Biol Psychiatry. 2011 Mar 15;69(6):526-33. doi: 10.1016/j.biopsych.2010.10.010. Epub 2010 Dec 17. Technique: Reporter-gene assays and miRNA overexpression experiments using a luciferase-based assay Sample: 203 Spanish patients with panic disorder and 341 control subjects. A sample of 201 anxiety patients and 642 control subjects from Finland and 102 panic disorder patients and 829 control subjects	2011

**C** Information about the gene

Info Articles Drugs miRNAs SNPs Regions Pathologies Pathways Transcription factors

Drugs (Articles)

Show 10 | 1 entries

OCDB class	OCDB score	Drug	Gene ID	Endogenous molecule	Action
1	-0.654	Caffeine	ADAR2A	Adenosine	<ul style="list-style-type: none"> <li>Action: <ul style="list-style-type: none"> <li>Antagonist</li> </ul> </li> <li>Category: <ul style="list-style-type: none"> <li>Appetite Depressants</li> <li>Central Nervous System Stimulants</li> <li>Phosphodiesterase Inhibitors</li> <li>Purergic P1 Receptor Antagonists</li> </ul> </li> <li>Indication: <ul style="list-style-type: none"> <li>Fatigue</li> <li>Ornithotic hyposthenia</li> <li>Short term treatment of apnea of prematurity in infants.</li> </ul> </li> <li>Pharmacodynamics: Caffeine, a naturally occurring xanthine derivative like theobromine and the bronchodilator theophylline, is used as a CNS stimulant, mild diuretic, and respiratory stimulant (in neonates with apnea of prematurity). Often combined with analgesics or with other skeletal caffeine is used to treat migraine and other headache types. Over the counter, caffeine is available to treat drowsiness or mild water-weight gain.</li> <li>Pathology effect: Caffeine produces mild psychomotor and sometimes anorectic effects by antagonizing adenosine at A1(1) and A2A receptors, and perhaps through interactions with other transmitter systems. Caffeine-induced anxiety (WAS) was also associated with two-locus interactions of selected ADAR2A and DRD2 polymorphisms.</li> <li>Pharmacological action: Yes</li> </ul>

**D** Information about the gene

Info Articles Drugs miRNAs SNPs Regions Pathologies Pathways Transcription factors

miRNAs (Articles)

Show 10 | 1 entries

OCDB class	OCDB score	miRNA
1	0.852	hsa-miR-333

miRNA target predictions (TargetScan)

miRNA
hsa-miR-1252
hsa-miR-1385
hsa-miR-1281
hsa-miR-15a
hsa-miR-15b
hsa-miR-18
hsa-miR-185
hsa-miR-1972
hsa-miR-214
hsa-miR-2982

miRNA target predictions (Mirabase)

No information available.

miRNA target predictions (Miranda)

miRNA
hsa-miR-34a
hsa-miR-182
hsa-miR-204
hsa-miR-211
hsa-miR-214
hsa-miR-215a
hsa-miR-134
hsa-miR-149
hsa-miR-192
hsa-miR-34a-5p

**Figure 2.** OCDB Interface. (A) General information about ADAR2A, links to HGNC and NCBI and the gene card download option. (B) Information about the articles mentioning results on ADAR2A are listed. (C) Drugs targeting ADAR2A taken from literature. The page reports also drugs targeting (not shown here) predicted by DT-Hybrid algorithm and taken from DrugBank. Other OCDB interface sections are not shown. (D) miRNAs mentioned in the articles targeting ADAR2A are given. Validated and predicted miRNAs from online databases targeting ADAR2A are listed.

- **Regions:** Regions give the chromosomal location of the selected item (i.e. a gene, miRNA, SNP); When the item is a drug, region yields the chromosomal location of targeted genes; When the item is a region, the list of genes, SNPs and miRNAs falling in such region are given together with the list of article citing such a region.
- **Pathologies:** Pathologies show pathologies in which the item is associated with OCD or with any other pathology

related to OCD (such as social phobia or schizophrenia in comorbidity with OCD), which has been reported in literature. Each pathology is associated to Disease-ontology code (57).

- **Transcription factors:** By using DAVID (52, 53), we have obtained transcription factors related to our gene set. For miRNAs, we retrieved from TransmiR (54) the genes-miRNAs regulations. Note the

update gene name of transcription is linked to Entrez as well as the gene-miRNAs regulation is linked to miRBase.

- **Pathways:** Pathways gives the list of pathways in which genes enter.

Users can visualize all details and relative relations with genetic elements present in the database of each item reported in the results cards by clicking 'see more'. This is useful to navigate inside the database.

### Browse.

This interface lists all genes, drugs, miRNAs, studies, SNPs and regions in OCDB. For all items, with the exception of studies, the relevance to the OCD is returned.

More precisely, when browsing for 'Gene', OCDB lists the gene name, its aliases and if it is a target of drugs used in OCD treatments. This section contains a tab to list all genes per chromosome. 'Drug' lists all names of drugs clinically used in OCD or related pathologies as reported in the articles in the OCDB. By clicking in 'miRNA' users can see the name and a description of the role of the miRNAs in the pathology. This is one of the sentences extracted from related articles. 'Studies' lists the year of publications, the title and PubMed-id. SNPs and Region-ids are listed in two distinct sections. 'Regions' are associated with markers, when available. In all browsing sections by clicking on 'see more', users can visualize the details and the relative relations with genetic elements present in OCDB.

The users can visualize the results in alphanumeric order with respect to any of the listed attributes. Moreover, a score representing the relevance of the gene, miRNA, drug, SNP or region with respect to the disease is given. For the earlier elements, users can order results in descending or ascending order by using such attribute scores.

### Statistics.

Statistics section reports the amount of data by category, with particular attention to the number of interactions by category. We refer to Figure 3 for the OCDB statistics. The number concerning the manually curated data are the following: 536 articles, 153 genes, 16 miRNAs, 180 SNPs, 48 drugs and 148 chromosomal locations. The data enriched by using external sources and predictions software are the following: 143 therapeutic indications from DrugBank, 50 pathways, 8701 gene and 566 miRNA transcription factor regulations, 37 435 MirTarBase predictions, 91 062 miRanda predictions, 146 125 TargetScan predictions, 59 218 DT-Hybrid predictions and 2276 DrugBank targeting relations.

### Documentation.

The documentation section shows general information about the aim and the structure of OCDB, and a description of OCD.

The database is free for all users, and we distribute the data under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License.

### Data maintenance


OCDB will be continuously updated, through manual screenings of new publications on PubMed (45) together with automatic procedures alerting new publications. Therefore, again the combination of manual and automatic procedures will extract and evaluate genetic information. After these steps OCDB will be updated.

In addition, researchers can suggest new or missing findings to be inserted in the database by contacting authors by email. Our contact information is reported in the 'Contact' page.

### Data distribution

#### Download/upload.

The whole database can be dumped, together with the SQL scripts, as a compressed archive.gz. Search results (i.e. by gene, miRNA, drug, article, SNP and region) can be downloaded in.txt or HTML format through the section 'Info'. Data are also available for download in tabular format.



**Figure 3.** Statistics on (A) the manually curated data and (B) data obtained by using external sources and predictions software.

## Utility and discussion

Through the literature screening several inferences regarding genes and treatments about OCD may come to light. Until present day, most studies have been conducted on the same genes and the same drugs related to OCD. Some drugs used for the treatment of obsessions do not have a great efficacy in the treatment of OCD and are often themselves cause of the disease (i.e. Risperidone). According to the fact that in the worldwide population OCD is more common than it is really perceived (with a prevalence of 2–3%) (12), our system OCDB can help to give a comprehensive view about the main genes, drugs or miRNAs involved in the pathology. By querying OCDB, researchers can make new hypothesis and infer novel knowledge.

### Case study 1

*DRD2* (D(2) dopamine receptor) and *ADORA2A* (adenosine A2a receptor) a correlation among OCD caffeine, nicotine and SSRIs

#### Prior knowledge.

*DRD2* (D(2) dopamine receptor) is involved in OCD (64), and *ADORA2A* (adenosine A2a receptor) is a validated target site of hsa-miR339 associated with panic disorder (65). Caffeine can produce anxiogenic effect antagonizing adenosine at A(2A) receptors, which are colocalized with dopamine receptors in the brain (66). In a healthy person the effects are irrelevant or can be different if associated with polymorphisms in the *ADORA2A* gene (66).

#### How to use OCDB.

Through OCDB we may know which are the drugs or molecules active on *ADORA2A* and *DRD2*. This can be easily obtained by querying OCDB through the following path: Search *ADORA2A* (the same applies for *DRD2*), then click on ‘Drugs’ in the tab-bar menu, browse prediction data in the section ‘Drug-targets (DT-Hybrid)’ in OCDB. The results indicated that the molecules active on that genes are caffeine and nicotine while one of the drugs is flvoxamine.

#### Posterior knowledge.

Pasquini *et al.* (67) present a case of OCD resistant to conventional treatments, which improved following nicotine augmentation administered as 4 mg chewing gum. Tizabi *et al.* (69) show as nicotine attenuates some symptoms of compulsive checking in a rat model of OCD.

#### Conclusion.

It could be interesting to investigate what effects the stimulation of these receptors produce in patients with

anxiogenic background such as OCD or panic disorder as well as the simultaneous use of caffeine and nicotine with flvoxamine.

### Case study 2

miRNAs prediction reporting on *DRD2* and *ADORA2A*.

#### Prior knowledge.

It is known that *ADORA2A* (adenosine A2a receptor) is a validated target site of hsa-miR339 associated with panic disorder (65).

#### How to use OCDB.

OCDB stores also predicted miRNAs on *ADORA2A* (see Table 1). This may be visualized through the following path: Search *ADORA2A*, click ‘miRNAs’ in tab-bar menu of such gene and use prediction data in the section ‘miRNA target predictions (miRanda)’. The same must be done for *DRD2*. We have used the prediction data from miRanda (61), but there are also predictions from TargetScan (59) and MirTarBase (60).

#### Posterior knowledge.

Among these, several miRNAs have been validated and predicted to be involved in OCD and panic disorder. For instance, miR-488 is a repressor of *POMC* (proopiomelanocortin) (65), miR-485-5p is associated with hoarding subtype of OCD (37), miR-204 and miR-211 are associated with *ALAD* (aminolevulinatodehydratase) in social phobia (69) and miR-339 is associated with panic disorder (65). In addition to having this data and using online resources, we have conducted a functional enrichment using WebGestalt (70) to individuate in which biological functions *DRD2* and *ADORA2A* are involved (see Table 1).

#### Conclusion.

The studies about the relation between miRNAs and OCD or some anxiety disorders are very recent. Only for few miRNAs, the function on this gene is known. Hence, the remaining predicted miRNAs could be interesting for further investigations (see Table 1).

### Case study 3

Polymorphisms in gene target, as in *SLC6A*, could influence treatments and the efficacy of drug therapies.

#### Prior knowledge.

Several OCD patients do not respond to conventional treatment. In OCD treatment, the main drug-targets are (i) SERT1 or 5-HTT solute carrier family 6 encoded by



**Table 1.** Association studies by using OCDB<sup>a</sup>

Genes	Predicted drugs (DT-Hybrid)	Predicted miRNAs (miRanda)	Description	Functional enrichment	References
DRD2 <sup>a</sup>	Caffeine, Nicotine, Fluvoxamine	miR-140-5p, miR-9, miR-150, miR-185, miR-190, miR-34c-5p, miR-377, miR-379, miR-330-5p, miR-326, miR-346, miR-449a, miR-181d, miR-539, miR-449b, miR-876-5p, miR-190b	No association reported in literature	Synaptic transmission, multicellular organismal signaling, transmission of nerve impulse, system process, neurological system process, neuron–neuron synaptic, <b>behavior</b> , regulation of synaptic transmission, regulation of transmission of nerve, regulation of neurological system, negative regulation of synaptic transmission, <b>learning or memory</b> , cell communication, startle response, response to drug, catecholamine transport, negative regulation of transmission of nerve impulse, drug binding, neurotransmitter receptor activity	Billett <i>et al.</i> (64)
ADORA2A <sup>a</sup>	Caffeine, Nicotine, Fluvoxamine	miR-182; miR-204, miR-211, miR-214, miR-216a, miR-134, miR-149, miR-150, miR-34c-5p, miR-378, miR-383, miR-330-5p, miR-328, miR-342-3p, miR-326, miR-339-5p, miR-422a, miR-485-5p, miR-488, miR-494, miR-542-3p, miR-543, miR-34a	miR-488 is a repressor of POMC <sup>c</sup> miR-339 associated with panic disorder <sup>c</sup> miR-485-5p is associated with hoarding subtype of OCD <sup>d</sup> miR-204 and miR-211 are associated with ALAD in social phobias	Neurological system process, neuron–neuron synaptic, <b>behavior</b> , regulation of synaptic transmission, regulation of system process, regulation of transmission of nerve impulse, regulation of transmission of nerve impulse, signaling, startle response, response to drug, catecholamine transport, trans-membrane signaling receptor activity	Billett <i>et al.</i> (64) Muiños-Gimeno <i>et al.</i> (65) Muiños-Gimeno <i>et al.</i> (37) Donner <i>et al.</i> (69)

<sup>a</sup>Starting from a gene involved in OCD, DRD2 and ADORA2A, which is a validated target of hsa-miR339 associated with panic disorder, we found predicted drugs and miRNAs for these genes. A functional enrichment is also reported. <sup>b</sup>Ref. (64). <sup>c</sup>Ref. (65). <sup>d</sup>Ref. (36). <sup>e</sup>Ref. (69).

*SLC6A4*, (ii) 5-hydroxytryptamine (serotonin) receptor 2C- G protein-coupled encoded by *HTR2C* and (iii) dopamine transporter encoded by *SLC6A3*.

#### How to use OCDB.

OCDB contains SNPs within genes, miRNAs, miRNA-targets and drug-targets. The SNPs and the predicted drugs in *SLC6A4* can be obtained in OCDB through the following path: Search *SLC6A4*, click ‘SNP’ in tab-bar menu and browse the main SNPs associated with OCD in *SLC6A4*; also click ‘Drug’ in tab-bar menu and browse prediction data in the section ‘Drug-targets (DT-Hybrid)’. The predicted drugs are phentermine, pregabalin, doxycycline, venlafaxine, amitriptyline and tolcapone.

#### Conclusion.

An SNP within a drug-target could influence treatment and the efficacy of drug therapy. Studying predicted drug

targets, researchers could make hypothesis on new drug combination for treatments.

#### Case study 4

Finding a validation between oxidative stress and anxiety disorder.

#### Prior knowledge.

Another point of investigation involves the oxidative stress. *GSTP1* (glutathione S-transferase pi 1) is a target of clomipramine, a TCAs (71).

#### How to use OCDB.

We have interrogated OCDB to know which are other gene targets of Clomipramine. This can be easily obtained by querying OCDB through the following path: Search in drug section Clomipramine, by clicking ‘Genes’ in tab-bar menu. The list shows *GSTP1*, *HTR2A*, *HTR2B*, *HTR2C*,

*SLC6A2* and *SLC6A4*. Then, we ask if each gene has glutathione as a predicted drug. Thus, by searching for each gene and clicking ‘Drugs’ in tab-bar menu, in the section ‘Drug target predictions (DT-Hydril)’ we discovered that some of these genes are targets of semisynthetic molecules like glutathione: glutathione sulfonic acid, S-(P-nitrobenzyl)-glutathione and S-hexylglutathione, (*HTR2B*, *HTR2C*, *SLC6A2*, *SLC6A4*).

#### Posterior knowledge.

There is an interest on the oxidative stress in the etiology and progression and prevention of psychiatric disorders (72). Strong emotions or emotional stress can lead to mental states of depression or anxiety, with substantial consequences on lifestyle and health (73). During drug therapy, some miRNAs could change their concentration and thus influence the expression of their target. For example in a study on mice, miR-16 targets *SERT*. After treatment with fluoxetine, i.e. a SSRI (selective serotonin reuptake inhibitors), the miR-16 level increased with a reduced *SERT* expression. This is a case in which miRNAs play a synergistic role in therapy (74).

#### Conclusion.

The oxidative stress could alter and disrupt the neural circuits, which might be the implications of the use of glutathione in the treatment of OCD. In addition, miRNAs could have unexpected implications in this pathology, because miRNAs regulate multiple pathways in the brain in which minimal changes in gene expression or regulation could be fatal (76).

## Conclusion

OCDB is the first online resource containing genomic information related to OCD. We have collected the information from bibliography on PubMed. We have enriched the database with prediction analysis of miRNAs and drugs. Users can browse the information in the database by category (genes, articles, miRNAs, drugs, chromosomal region, SNP and drug target) or starting by searching a specific element (e.g. gene) and retrieve all connected information (targeting miRNAs, drugs and so on). By looking at OCDB, researchers can create a possible panel of genomic elements involved in the pathophysiology of disease. Finally, OCDB can provide the basis for further hypothesis and application of outcomes in the medium to long term.

## Acknowledgements

The authors thank Dr Salvatore Alaimo, from University of Catania, for providing us drug target predictions data. They thank Dr Francesco Russo, from University of Pisa for his useful suggestions.

They thank Prof. Ayrton Field for the revising of English of the article. They thank every person with this disease and above all who has inspired this idea and this work.

## Funding

Publication of this article has been funded by PON 2007–2013 grant, SIGMA -PON01 00683 – CUP B61H11000380005. RG, AP and AF have been founded by Programma Operativo Fondo Europeo per lo Sviluppo Regionale (PO-FESR 2007–2013), Linea di intervento 4.1.1.2. Grant number: CUP G23F11000840004. Funding for open access charge: Ministero dell’Istruzione, dell’Università e della Ricerca (MIUR) and Unione Europea Fondo europeo di Sviluppo regionale Ministero dello sviluppo economico

*Conflict of interest.* None declared.

## References

1. Mataix-Cols,D., Rosario-Campos,M. and Leckman,J. (2005) A multidimensional model of obsessive-compulsive disorder. *Am. J. Psychiatry*, **162**, 228–238.
2. Mataix-Cols,D. (2006) Deconstructing obsessive-compulsive disorder: a multidimensional perspective. *Curr. Opin. Psychiatry*, **19**, 84–89.
3. Geller,D., Biederman,J., Jones,J. *et al.* (1998) Obsessive-compulsive disorder in children and adolescents: a review. *Harv. Rev. Psychiatry*, **5**, 260–273.
4. Rosario-Campos,M., Leckman,J., Mercadante,M. *et al.* (2001) Adults with early-onset obsessive-compulsive disorder. *Am. J. Psychiatry*, **158**, 1899–1903.
5. Rasmussen,S. and Eisen,J. (1992) The epidemiology and clinical features of obsessive-compulsive disorder. *Psychiatr. Clin. North Am.*, **15**, 743–758.
6. Kessler,R., Berglund,P., Demler,O. *et al.* (2005) Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the national comorbidity survey replication. *Arch. Gen. Psychiatry*, **62**, 593–602.
7. World Health Organization. (2010) *International statistical classification of diseases and related health problems*, 10th revision. Geneva, World Health Organization. Available: <http://apps.who.int/classifications/icd10/browse/2010/en#/I20-I25> Accessed 28 Jan 2011.
8. American Psychiatric Association. (2000) *Diagnostic and Statistical Manual of Mental Disorders*, 4th edn, Text Rev. American Psychiatric Association ISBN: 978-0-89042-025-6.
9. American Psychiatric Association. (2013): *Diagnostic and Statistical Manual of Mental Disorders* (Fifth ed.). Arlington, VA: American Psychiatric Publishing. ISBN 978-0-89042-555-8.
10. American Psychiatric Association. (2013) *Highlights of Changes from DSM-IV-TR to DSM-5*. Arlington, VA: American Psychiatric Association.
11. Van Ameringen,M., Patterson,B. and Simpson,W. (2014) DSM-5 obsessive-compulsive and related disorders: clinical implications of new criteria. *Depress. Anxiety*, **31**, 487–493.
12. Murray,C. and Lopez,A. (1996) *Global Burden of Disease: A Comprehensive Assessment of Mortality and Morbidity From Diseases, Injuries and Risk Factors in 1990 and Projected to 2020*. The Lancet, **349**, 9064, 1498-1504, 1997.

13. Pitman,R. (1984) Janet's obsessions and psychasthenia: a synopsis. *Psychiatr. Q.*, **56**, 291–314.
14. Hanna,G., Veenstra-VanderWeele,J., Cox,N. *et al.* (2002) Genome-wide linkage analysis of families with obsessive compulsive disorder ascertained through pediatric probands. *Am. J. Med. Genet.*, **114**, 541–552.
15. Willour,V., Yao Shugart,Y., Samuels,J. *et al.* (2004) Replication study supports evidence for linkage to 9p24 in obsessive-compulsive disorder. *Am. J. Hum. Genet.*, **75**, 508–513.
16. Nestadt,G., Samuels,J. and Riddle,M. (2000) A family study of obsessive-compulsive disorder. *Arch. Gen. Psychiatry*, **57**, 358–363.
17. do Rosario-Campos,M.C., Leckman,J., Curi,M. *et al.* (2005) A family study of early-onset obsessive-compulsive disorder. *Am. J. Med. Genet. B Neuropsychiatr. Genet.*, **136B**, 92–97.
18. Hanna,G., Himle,J., Curtis G. *et al.* (2005) A family study of obsessive-compulsive disorder with pediatric probands. *Am. J. Med. Genet. B Neuropsychiatr. Genet.*, **134B**, 13–19.
19. Bienvenu,O., Samuels,J., Riddle,M. *et al.* (2000) The relationship of obsessive-compulsive disorder to possible spectrum disorders: results from a family study. *Biol. Psychiatry*, **48**, 287–293.
20. Grados,M., Riddle,M., Samuels,J. *et al.* (2001) The familial phenotype of obsessive-compulsive disorder in relation to tic disorders: the Hopkins ocd family study. *Biol. Psychiatry*, **50**, 559–565.
21. Hettema,J., Neale,M. and Kendler,K. (2001) A review and meta-analysis of the genetic epidemiology of anxiety disorders. *Am. J. Psychiatry*, **158**, 1568–1578.
22. Veenstra-VanderWeele,J., Kim,S., Gonen,D. *et al.* (2001) Genomic organization of the *slc11a1/eaac1* gene and mutation screening in early-onset obsessive-compulsive disorder. *Mol. Psychiatry*, **6**, 160–167.
23. Arnold,P., Sicard,T., Burroughs,E. *et al.* (2006) Glutamate transporter gene *slc11a1* associated with obsessive-compulsive disorder. *Arch. Gen. Psychiatry*, **63**, 769–776.
24. Kanai, Y., Hediger,M. (2004) The glutamate/neutral amino acid transporter family *slc1*: molecular, physiological and pharmacological aspects. *Pflugers Arch.*, **447**, 469–479.
25. Bonelli,R. and Cummings,J. (2007) Frontal-subcortical circuitry and behavior. *Dialogues Clin. Neurosci.*, **9**, 141–151.
26. Bloch,M. and Pittenger,C. (2010) The genetics of obsessive-compulsive disorder. *Curr. Psychiatry Rev.*, **6**, 91–103.
27. McDougle,C., Epperson,C., Price,L. *et al.* (1998) Evidence for linkage disequilibrium between serotonin transporter protein gene (*slc6a4*) and obsessive compulsive disorder. *Mol. Psychiatry*, **3**, 270–273.
28. Lei,X., Chen,C., He,Q. *et al.* (2012) Sex determines which section of the *slc6a4* gene is linked to obsessive-compulsive symptoms in normal Chinese college students. *J. Psychiatr. Res.*, **46**, 1153–1160.
29. Frisch,A., Michaelovsky,E., Rockah,R. *et al.* (2000) Association between obsessive-compulsive disorder and polymorphisms of genes encoding components of the serotonergic and dopaminergic pathways. *Eur. Neuropsychopharmacol.*, **10**, 205–209.
30. Meira-Lima,I., Shavitt,R. and Migueta,K. (2004) Association analysis of the catechol-o-methyltransferase (*comt*), serotonin transporter (*5-htt*) and serotonin 2a receptor (*5ht2a*) gene polymorphisms with obsessive-compulsive disorder. *Genes Brain Behav.*, **3**, 75–79.
31. Alonso,P., Gratacòs,M., Menchon,J. *et al.* (2008) Genetic susceptibility to obsessive-compulsive hoarding: the contribution of neurotrophic tyrosine kinase receptor type 3 gene. *Genes Brain Behav.*, **7**, 778–785.
32. Ozomaro,U., Cai,G., Kajiwara,Y. *et al.* (2013) Characterization of *slitrk1* variation in obsessive-compulsive disorder. *PLoS One*, **8**, e70376.
33. Sun,B. and Tsao,H. (2008) Small RNAs in development and disease. *J. Am. Acad. Dermatol.*, **59**, 725–737.
34. Malan-Muller,S., Hemmings,S. and Seedat,S. (2013) Big effects of small RNAs: a review of microRNAs in anxiety. *Mol. Neurobiol.*, **47**, 726–739.
35. Kawaji,H. and Hayashizaki,Y. (2008) Exploration of small RNAs. *PLoS Genet.*, **4**, 22.0.
36. Filipowicz,W., Bhattacharyya,S. and Sonenberg,N. (2008) Mechanisms of posttranscriptional regulation by microRNAs: are the answers in sight? *Nat. Rev. Genet.*, **9**, 102–114.
37. Muñios-Gimeno,M., Guidi,M., Kagerbauer,B. *et al.* (2009) Allele variants in functional microRNA target sites of the neurotrophin-3receptor gene (*ntrk3*) as susceptibility factors for anxiety disorders. *Hum. Mutat.*, **30**, 1062–1071.
38. Basoglu,M., Lax,T., Kasvikis,Y. *et al.* (1988) Predictors of improvement in obsessive-compulsive disorder. *J. Anxiety Disord.*, **2**, 299–317.
39. Bandelow,B., Zohar,J., Hollander,E. *et al.* (2008) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders-first revision. *World J. Biol. Psychiatry*, **9**, 248–312.
40. Kellner,M. (2010) Drug treatment of obsessive-compulsive disorder. *Dialogues Clin. Neurosci.*, **12**, 187–197.
41. Franklin,M. and Foa,E. (2011) Treatment of obsessive compulsive disorder. *Annu. Rev. Clin. Psychol.*, **7**, 229–243.
42. De Berardis,D., Serroni,N., Marini,S. *et al.* (2012) Agomelatine augmentation of escitalopram therapy in treatment resistant obsessive-compulsive disorder: a case report. *Case Rep. Psychiatry*, **2012**, 642752.
43. De Berardis,D., Di Iorio,G., Acciavatti,T. *et al.* (2011) The emerging role of melatonin agonists in the treatment of major depression: focus on agomelatine. *CNS Neurol. Disord. Drug Targets*, **10**, 119–132.
44. Goodman,W., Price,L., Rasmussen,S. *et al.* (1989) Theyale-brown obsessive compulsive scale. i. development, use, and reliability. *Arch. Gen. Psychiatry*, **46**, 1006–1011.
45. Macleod,M.R. (2002) Pubmed: <http://www.pubmed.org>. *J. Neurol. Neurosurg. Psychiatry*, **73**, 746.
46. Maglott,D., Ostell,J., Pruitt,KD. *et al.* (2011) Entrez Gene: gene-centered information at NCBI. *Nucleic Acids Res.*, **39**, D52–D57.
47. Povey,S., Lovering,R., Bruford,E. *et al.* (2001) The hugo gene nomenclature committee (hgnc). *Hum. Genet.*, **109**, 678–680.
48. Sherry,S., Ward,M., Kholodov,M. *et al.* (2001) dbsnp: the ncbi database of genetic variation. *Nucleic Acids Res.*, **29**, 308–311.
49. Knox,C., Law,V., Jewison,T. *et al.* (2011) Drugbank 3.0: a comprehensive resource for 'omics' research on drugs. *Nucleic Acids Res.*, **5(Database issue)**, 1035–1041.

50. Griths-Jones,S., Grocock,R., van Dongen,S. *et al.* (2006) mir-base: microRNA sequences, targets and gene nomenclature. *Nucleic Acids Res.*, **34**(Database issue), 140–144.
51. Bolton,E., Wang,Y., Thiessen,S. *et al.* (2008) PubChem: integrated platform of small molecules and biological activities. Chapter 12 IN Wheeler RA and Spellmeyer DC, eds. Annual Reports in Computational Chemistry, Volume 4. Oxford, UK: Elsevier, **4**, 217–241.
52. Huang,D.W., Sherman,B.T. and Lempicki,R.A. (2008) Systematic and integrative analysis of large gene lists using DAVID Bioinformatics Resources. *Nat. Protoc.*, **4**, 44–57.
53. Huang,D.W., Sherman,B.T. and Lempicki,R.A. (2009) Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. *Nucleic Acids Res.*, **37**, 1–13.
54. Wang,J., Lu,M., Qiu,C. *et al.* (2010) TransmiR: a transcription factor-microRNA regulation database. *Nucleic Acids Res.*, **38**(Database issue), D119–D122.
55. Kanehisa,M., Goto,S., Sato,Y. *et al.* (2014) Data, information, knowledge and principle: back to metabolism in KEGG. *Nucleic Acids Res.*, **42**, D199–D205.
56. Kanehisa,M. and Goto,S. (2002) KEGG: kyoto encyclopedia of genes and genomes. *Nucleic Acids Res.*, **28**, 27–30.
57. Wu,T.-J., Schriml,L.M., Chen,Q.-R. *et al.* (2015) Generating a focused view of disease ontology cancer terms for pan-cancer data integration and analysis. *Database* (Oxford), 2015:bav032.
58. Degtyarenko,K., de Matos,P., Ennis,M. *et al.* (2008) ChEBI: a database and ontology for chemical entities of biological interest. *Nucleic Acids Res.*, **36**(Database issue), D344–D350.
59. Lewis,B., Shih,I., Jones-Rhoades,M. *et al.* (2003) Prediction of mammalian microRNA targets. *Cell*, **115**, 787–798.
60. Hsu,S., Lin,F., Wu,W. *et al.* (2011) mirtarbase: a database curates experimentally validated microRNA-target interactions. *Nucleic Acids Res.*, **39**(Database issue), 163–169.
61. John,B., Enright,A., Aravin,A. *et al.* (2004) Human microRNA targets. *PLoS Biol.*, **2**, 363.
62. Alaimo,S., Pulvirenti,A., Giugno,R. *et al.* (2013) Drug-target interaction prediction through domain-tuned network-based inference. *Bioinformatics*, **29**, 2004–2008.
63. Kim,J., Kim,H., Yoon,Y. *et al.* (2015) LGscore: a method to identify disease-related genes using biological literature and Google data. *J. Biomed. Inform.*, **54**, 270–282.
64. Billett,E., Richter,M., Sam,F. *et al.* (1998) Investigation of dopamine system genes in obsessive-compulsive disorder. *Psychiatr. Genet.*, **8**, 163–169.
65. Muiños-Gimeno,M., Espinosa-Parrilla,Y., Guidi,M. *et al.* (2011) Human microRNAs mir-22, mir-138-2, mir-148a, and mir-488 are associated with panic disorder and regulate several anxiety candidate genes and related pathways. *Biol. Psychiatry*, **69**, 526–533.
66. Childs,E., Hoho, C., Deckert,J. *et al.* (2008) Association between *adora2a* and *drd2* polymorphisms and caffeine-induced anxiety. *Neuropsychopharmacology*, **33**, 2791–2800.
67. Pasquini,M., Garavini,A. and Biondi,M. (2005) Nicotine augmentation for refractory obsessive-compulsive disorder. A case report. *Prog. Neuropsychopharmacol. Biol. Psychiatry*, **29**, 157–159.
68. Tizabi,Y., Louis,V.A., Taylor,C.T. *et al.* (2002) Effect of nicotine on quinpirole-induced checking behavior in rats: implications for obsessive-compulsive disorder. *Biol Psychiatry*, **51**, 164–171.
69. Donner,J., Pirkola,S., Silander,K. *et al.* (2008) An association analysis of murine anxiety genes in humans implicates novel candidate genes for anxiety disorders. *Biol. Psychiatry*, **64**, 672–680.
70. Zhang,B., Kirov,S. and Snoddy,J. (2005) Webgestalt: an integrated system for exploring gene sets in various biological contexts. *Nucleic Acids Res.*, **33**, 741–748.
71. Baranczyk-Kuzma,A., Kuzma,M. and Gutowicz,M. (2004) Glutathione s-transferase pi as a target for tricyclic antidepressants in human brain. *Acta Biochim. Pol.*, **51**, 207–212.
72. Hassan,W., Silva,C., Mohammadzai,I. *et al.* (2014) Association of oxidative stress to the genesis of anxiety: implications for possible therapeutic interventions. *Curr. Neuropharmacol.*, **12**, 120–139.
73. Fa,M., Xia,L., Anunu,R. *et al.* (2014) Stress modulation of hippocampal activity - spotlight on the dentate gyrus. *Neurobiol. Learn. Mem.*, **112**, 53–60.
74. Baudry,A., Mouillet-Richard,S., Schneider,B. *et al.* (2010) mir-16 targets the serotonin transporter: a new facet for adaptive responses to antidepressants. *Science*, **329**, 1537–1541.
75. Espinosa-Parrilla,Y. and Muiños-Gimeno,M. (2011) MicroRNA-mediated regulation and the genetic susceptibility to anxiety disorders. In: Anxiety Disorders, Prof. Vladimir Kalinin (ed). ISBN: 978-953-307-592-1, InTech, DOI: 10.5772/21702.